Clinical Trials

298 enrolled

Carcinoma, Renal Cell

NCT06952621 2026-01-30

TD-NEOE3V3

390 enrolled

Esophageal Squamous Cell Carcinoma

NCT07371897 2026-01-28

SHINE

154 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07362186 2026-01-23

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

400 enrolled

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

300 enrolled

Nasopharyngeal Carcinoma

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

400 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07251582 2025-11-26

LungTime-C02

156 enrolled

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

NCT07246330 2025-11-24

Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study

340 enrolled

Esophageal Squamous Cell Carcinoma

NCT07177794 2025-09-17

EC-CRT-008

242 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06235203 2025-06-03

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

154 enrolled

Nasopharyngeal Carcinoma

NCT06977893 2025-05-18

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

194 enrolled

Breast

Breast Neoplasms

NCT05342194 2025-04-23

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

480 enrolled

Cholangiocarcinoma

NCT06712888 2025-03-18

Navigation

466 enrolled

Nasopharyngeal Carcinoma

NCT06437977 2025-03-13

neoR-TORCH

478 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06170489 2025-02-28

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

185 enrolled

Lymphoid

Hodgkin Disease

NCT04709380 2025-02-26

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Phase 3 Terminated

36 enrolled

Phase 3 Active not recruiting

Radiotherapy

NCT05869227 2024-12-30

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

166 enrolled

Nasopharyngeal Carcinoma

NCT06647563 2024-10-18

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

355 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT06592326 2024-09-19

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

460 enrolled

Carcinoma, Transitional Cell

NCT06095583 2024-06-21

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

756 enrolled

Small Cell Lung Carcinoma

NCT06277050 2024-04-30

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

264 enrolled

Nasopharyngeal Carcinoma

NCT06201065 2024-01-11

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

200 enrolled

Carcinoma, Hepatocellular

NCT05302284 2023-12-18

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

452 enrolled

Carcinoma, Transitional Cell

NCT06026878 2023-09-07

GNT Induction Treatment in Locally Advanced NPC

228 enrolled

Nasopharyngeal Carcinoma

NCT03856411 2023-02-01

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Phase 3 Completed

465 enrolled

Treatment-naive Advanced Non-small Cell Lung Cancer

NCT05340491 2022-08-31

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

212 enrolled

Nasopharyngeal Carcinoma

NCT05056337 2021-09-24

Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

Phase 3 Unknown

220 enrolled

Carcinoma, Hepatocellular

NCT04376866 2021-07-20

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

204 enrolled

Nasopharyngeal Carcinoma

NCT04778956 2021-03-04

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

218 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT04711434 2021-01-20

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Phase 3 Unknown

260 enrolled

Colorectal Neoplasms, Hereditary Nonpolyposis

NCT04568304 2020-09-29

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Phase 3 Unknown

364 enrolled

Carcinoma, Transitional Cell

NCT04453813 2020-09-28

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

226 enrolled